{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:35:57Z","timestamp":1787027757913,"version":"build-2736575974"},"reference-count":241,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple Myeloma (MM) remains a difficult to treat disease mainly due to its biological heterogeneity, of which we are more and more knowledgeable thanks to the development of increasingly sensitive molecular methods that allow us to build better prognostication models. The biological diversity translates into a wide range of clinical outcomes from long-lasting remission in some patients to very early relapse in others. In NDMM transplant eligible (TE) patients, the incorporation of mAb as daratumumab in the induction regimens, followed by autologous stem cell transplantation (ASCT) and consolidation\/maintenance therapy, has led to a significant improvement of PFS and OS.; however, this outcome remains poor in ultra-high risk MM or in those who did not achieve a minimal residual disease (MRD) negativity. Several trials are exploring cytogenetic risk-adapted and MRD-driven therapies in these patients. Similarly, quadruplets-containing daratumumab, particularly when administered as continuous therapies, have improved outcome of patients not eligible for autologous transplant (NTE). Patients who become refractory to conventional therapies have noticeably poor outcomes, making their treatment a difficult challenge in need of novel strategies. In this review, we will focus on the main points regarding risk stratification, treatment and monitoring of MM, highlighting the most recent evidence that could modify the management of this still incurable disease.<\/jats:p>","DOI":"10.3390\/cancers15082203","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:19:54Z","timestamp":1681096794000},"page":"2203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current Main Topics in Multiple Myeloma"],"prefix":"10.3390","volume":"15","author":[{"given":"Sonia","family":"Mor\u00e8","sequence":"first","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Medicina, Ospedale Profili, 60044 Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Maria","family":"Manieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1182\/blood-2022-165338","article-title":"Long term survival in multiple myeloma patients: A multicenter Italian experience","volume":"140","author":"Fazio","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Acon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"1","article-title":"Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre","volume":"17","author":"Corvatta","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Schavgoulidze, A., Lauwers-Cances, V., Perrot, A., Cazaubiel, T., Chretien, M.-L., Moreau, P., Facon, T., Leleu, X., Karlin, L., and Stoppa, A.-M. (2022). Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. Haematologica, Online ahead of print.","DOI":"10.3324\/haematol.2021.280566"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: Beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.bbmt.2018.12.141","article-title":"Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma","volume":"25","author":"Gopalakrishnan","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) Report within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: A meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: How to treat at diagnosis and relapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.3389\/fonc.2022.1096852","article-title":"Experts\u2019 consensus on the definition and management of high risk multiple myeloma","volume":"12","author":"Marcon","year":"2023","journal-title":"Front.Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.25758","article-title":"A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma","volume":"95","author":"Jurczyszyn","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-020-0307-4","article-title":"Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents","volume":"10","author":"Mina","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor?","volume":"117","author":"Malard","year":"2011","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.938392","article-title":"The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients","volume":"12","author":"You","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S2152-2650(21)02127-3","article-title":"Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients","volume":"21","author":"Belotti","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9993","DOI":"10.1182\/blood-2022-158693","article-title":"The co-occurrence of 1q21+\/1q23+ and t(4;14) abnormalities with specific clone size is predictive of shorter response to transplant in patients with multiple myeloma","volume":"140","author":"Ozga","year":"2022","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2019-130092","article-title":"Significance of modified risk stratification Msmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma","volume":"134","author":"Garifullin","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/s41598-020-62885-0","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2022.03.005","article-title":"Presentation and impact of double and triple hit cytogenetics in patients with multiple myeloma in the real world","volume":"22","author":"Singh","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clml.2019.01.003","article-title":"Next generation sequencing-based validation of the Revised International Staging System for multiple myeloma: An analysis of the MMRF CoMMpass Study","volume":"19","author":"Goldsmith","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"Zaccaria","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmoldx.2020.10.010","article-title":"Analytical validation of SKY92 for the identification of high-risk multiple myeloma","volume":"23","author":"Huigh","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41375-021-01286-2","article-title":"Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data","volume":"35","author":"Orgueira","year":"2021","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e760","DOI":"10.1097\/HS9.0000000000000760","article-title":"Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model","volume":"6","author":"Mateos","year":"2022","journal-title":"Hemasphere"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","article-title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: The HOVON-87\/NMSG-18 trial","volume":"4","author":"Kuiper","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2022-163848","article-title":"Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling","volume":"140","author":"Zhou","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.21.01217","article-title":"Identification of High-Risk Multiple Myeloma with a Plasma Cell Leukemia-Like Transcriptomic Profile","volume":"40","author":"Bruinink","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2022-170249","article-title":"Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification","volume":"140","author":"Bruinink","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: Description of Durie\/Salmon plus staging system","volume":"42","author":"Durie","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.25709","article-title":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells","volume":"95","author":"Gonsalves","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cheng, Q., Cai, L., Zhang, Y., Chen, L., Hu, Y., and Sun, C. (2021). Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.639528"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"566804","DOI":"10.3389\/fonc.2020.566804","article-title":"Proteomic alterations in multiple myeloma: A comprehensive study using bone marrow interstitial fluid and serum samples","volume":"10","author":"Chanukuppa","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of Mass Spectrometry in patients with newly-diagnosed Multiple Myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2022-156898","article-title":"Minimal residual disease monitoring by targeted Mass Spectrometry allows early relapse detection in multiple myeloma","volume":"140","author":"Noori","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2022-167430","article-title":"Persistance or reappearance of serum monoclonal protein detected by Mass Spectrometry is a major prognostic factor in patients with newly diagnosed multiple myeloma","volume":"140","author":"Claveau","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"668099","DOI":"10.3389\/fonc.2021.668099","article-title":"Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma","volume":"11","author":"He","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma\u2014Controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev."},{"key":"ref_57","first-page":"315","article-title":"Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Cedena","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2009.009100","article-title":"Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients","volume":"94","author":"Paiva","year":"2009","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.13484","article-title":"Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics","volume":"170","author":"Vagnoni","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","article-title":"Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients","volume":"20","author":"Parmar","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2022-162689","article-title":"Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis","volume":"140","author":"Kostopoulos","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","article-title":"The prognostic significance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2021006","DOI":"10.4084\/mjhid.2021.006","article-title":"Socioeconomic status is globally a prognostic factor for overall survival of multiple myeloma patients: Synthesis of studies and review of the literature","volume":"13","author":"Intzes","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14656566.2017.1418856","article-title":"Triplet vs. doublet drug regimens for managing multiple myeloma","volume":"19","author":"Offidani","year":"2018","journal-title":"Expert. Opinion. Pharmacother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V130.Suppl_1.905.905","article-title":"Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): Results from the Pethema\/GEM2012 Trial","volume":"130","author":"Paiva","year":"2017","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2021.39.15_suppl.8004","article-title":"Daratumumab maintenance or observation after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant in patients with newly diagnosed multiple myeloma: CASSIOPEIA Part 2","volume":"39","author":"Moreau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-137109","article-title":"Daratumumab (dara) + lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Final analysis of GRIFFIN","volume":"136","author":"Kaufman","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2021-146040","article-title":"Daratumumab plus ixazomib, lenalidomide, and dexamethasone as extended induction and consolidation followed by lenalidomide maintenance in standard-risk transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (IFM 2018-01): A phase II study of the IFM group","volume":"138","author":"Perrot","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: Results from the randomized phase III GMMG-HD6 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2022-162178","article-title":"Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in transplant-ineligible real-life multiple myeloma patients: Updated results of the randomized phase IV Real MM trial","volume":"140","author":"Bringhen","year":"2022","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1182\/blood-2022-163494","article-title":"Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the Phase 3 Maia Study","volume":"140","author":"Moreau","year":"2022","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10157","DOI":"10.1182\/blood-2022-163347","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the Phase 3 Alcyone Study","volume":"140","author":"Mateos","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: Efficacy and safety analysis of the Phase 3 IFM2017-03 Trial","volume":"140","author":"Manier","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1182\/blood-2022-168742","article-title":"Multicenter open label phase 3 study of isatuximab plus lenalidomide and dexamethasone with\/without bortezomib in the treatment of newly diagnosed non-frail transplant ineligible multiple myeloma elderly patients (\u226565; <80 Years). IFM2020-05\/Benefit","volume":"140","author":"Bobin","year":"2022","journal-title":"Blood"},{"key":"ref_84","first-page":"39","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 Trial","volume":"140","author":"Perrot","year":"2022","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","article-title":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib\u2013cyclophosphamide\u2013dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): A randomised, phase 2, non-inferiority trial","volume":"10","author":"Yong","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: A randomized phase 3 study (EMagine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","article-title":"Long-term outcome of a prospective randomized trial comparing continuous lenalidomide\/dexamethasone with lenalidomide\/dexamethasone induction, MEL140 with autologous blood stem Cell transplantation and single agent lenalidomide maintenance in patients of age 60-75 years with newly diagnosed multiple myeloma","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood-2022-160381","article-title":"Quadruplet induction, autologous transplantation and minimal residual disease adapted consolidation and treatment cessation in older adults \u226570y with newly diagnosed multiple myeloma: A subgroup analysis of the Master Trial","volume":"140","author":"Giri","year":"2022","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and maintenance in newly diagnosed multiple myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2022-168723","article-title":"Second primary malignancy incidence in patients receiving lenalidomide at induction and maintenance; long-term follow up of 4358 patients enrolled to the Myeloma XI Trial","volume":"140","author":"Jones","year":"2022","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2022-165376","article-title":"Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant\u2014Data from the Myeloma XI Trial","volume":"140","author":"Pawlyn","year":"2022","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): An open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2021-146798","article-title":"Ixazomib plus lenalidomide\/dexamethasone (IRd) versus lenalidomide \/dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: Results of the Spanish GEM2014MAIN Trial","volume":"138","author":"Rosinol","year":"2021","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): Interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","article-title":"KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma","volume":"57","author":"Gaballa","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood-2022-169161","article-title":"Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) As induction therapy in newly diagnosed high-risk multiple myeloma","volume":"140","author":"Tan","year":"2022","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"260.e1","DOI":"10.1016\/j.jtct.2023.01.010","article-title":"Autologous stem cell transplantation for patients with multiple myeloma with translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1182\/blood-2022-160451","article-title":"Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the Griffin and Master studies","volume":"140","author":"Callander","year":"2022","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1080\/10428194.2022.2123229","article-title":"Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA\/Spanish Myeloma Group (GEM)","volume":"63","author":"Villalba","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Panopoulou, A., Cairns, D.A., Holroyd, A.E., Nichols, I., Cray, N., Pawlyn, C., Cook, G., Drayson, M.T., Boyd, K.D., and Davies, F.E. (2022). Optimizing the value of lenalidomide maintenance by genetic profiling\u2014An analysis of 556 Myeloma XI trial patients. Blood, Online ahead of print.","DOI":"10.1182\/blood.2022018339"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","article-title":"Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04","volume":"40","author":"Touzeau","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2022-156309","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: Planned interim analysis of the GMMG-Concept Trial","volume":"140","author":"Weisel","year":"2022","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2022-159540","article-title":"Extended intensified post-ASCT consolidation with daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) for ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL): The UK Optimum\/Muknine Trial","volume":"140","author":"Kaiser","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2022-162295","article-title":"Phase I open-label single-arm study of BCMA\/CD19 dual-targeting FasTCAR-T Cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"140","author":"Du","year":"2022","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease following autologous stem cell transplant for patients with myeloma: Prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"Pawlyn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2022-165441","article-title":"Clinical impact of next generation flow in bone marrow vs Qip-Mass Spectrometry in peripheral blood to assess minimal residual disease in newly diagnosed multiple myeloma patients receiving maintenance as part of the GEM2014MAIN Trial","volume":"140","author":"Puig","year":"2022","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2022-167382","article-title":"Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using Bloodflow","volume":"140","author":"Notarfranchi","year":"2022","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Prognostic value of positron emission tomography-computed tomography (PRT-CT) at dagnosis and follow-upin transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: Results of the Cassiopet Companion Study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1182\/blood-2022-156730","article-title":"Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and autologous transplantation: Extended follow up of the Master Trial","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2022-168842","article-title":"Risk-adapted therapy directed according to response (RADAR, UK-MRA Myeloma XV)\u2014Comparing MRD-guided treatment escalation and de-escalation strategies in patients with newly diagnosed myeloma suitable for stem cell transplantation","volume":"140","author":"Yong","year":"2022","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.annonc.2022.04.013","article-title":"VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)","volume":"33","author":"Moreau","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2022-159105","article-title":"Isatuximab Plus Carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: Ikema subgroup analysis","volume":"140","author":"Facon","year":"2022","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1182\/blood-2022-162731","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: Ikema subgroup analysis by number of prior lines of treatment","volume":"140","author":"Capra","year":"2022","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase-III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): Overall survival results from the Phase 3 Apollo Study","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood-2022-159710","article-title":"Isatuximab plus pomalidomide\/low-dose dexamethasone versus pomalidomide\/low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (ICARIA-MM): Characterization of subsequent antimyeloma therapies","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: Final overall survival analysis from the randomized phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1182\/blood-2022-164656","article-title":"Phase II trial of elotuzumab with pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma (RRMM) in the post-daratumumab progression setting","volume":"140","author":"Ailawadhi","year":"2022","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1182\/blood-2022-159424","article-title":"Retreatment of patients with anti CD38-based combinations in multiple myeloma in real-life: Results from the Emmy Cohort Study","volume":"140","author":"Hulin","year":"2022","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1182\/blood-2022-164877","article-title":"Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 Trial","volume":"140","author":"Nooka","year":"2022","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2022-156035","article-title":"Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-life setting: The ALFA Study","volume":"140","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2022-158538","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma included in the compassionate use or the expanded access program. Experience with a Spanish Cohort","volume":"140","author":"Alonso","year":"2022","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2022-171077","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma, a real-world single center experience","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1182\/blood-2022-166399","article-title":"Belantamab mafodotin in patients with relapsed and refractory multiple myeloma who have received at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody: A retro-prospective Italian observational study","volume":"140","author":"Offidani","year":"2022","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1182\/blood-2021-147101","article-title":"Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed\/efractory multiple myeloma (RRMM)","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1182\/blood-2022-160445","article-title":"Belantamab mafodotin in combination with pomalidomide and dexamethasone demonstrates durable responses in triple class exposed\/refractory multiple myeloma","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139181","article-title":"DREAMM-7: A phase III study of the efficacy and safety of belantamab mafodotin (Belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Rifkin","year":"2020","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139785","article-title":"DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory Multiple Myeloma (RRMM)","volume":"136","author":"Trudel","year":"2020","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","article-title":"Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HOR","volume":"22","author":"Weisel","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2022.40.16_suppl.8018","article-title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 Study","volume":"16","author":"Suvannasankha","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2021-152662","article-title":"DREAMM-5 Study: Investigating the synergetic effects of belantamab mafodotin plus inducible T-Cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Callander","year":"2021","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2021-153315","article-title":"DREAMM-9: Phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma","volume":"138","author":"Usmani","year":"2021","journal-title":"Blood"},{"key":"ref_166","first-page":"2736","article-title":"A phase 1\/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"140","author":"Terpos","year":"2022","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"7286","DOI":"10.1182\/blood-2022-162584","article-title":"Belantamab mafodotin in combination with Vrd for the treatment of newly diagnosed transplant eligible multiple myeloma patients: Results from the Phase II, open label, multicenter, GEM-BELA-Vrd Trial","volume":"140","author":"Ocio","year":"2022","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.HS9.0000843604.69106.e8","article-title":"S178: Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A Phase 1\/2 study by the hellenic society of Hematology","volume":"6","author":"Terpos","year":"2022","journal-title":"HemaSphere"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2021-152224","article-title":"Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14","volume":"138","author":"Hultcrantz","year":"2021","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) Monotherapy in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and\/or Refractory CD\u201356-positive Multiple Myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen bite molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-Cell Maturation Antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Correlative analyses from MajesTEC-1","volume":"140","author":"Casneuf","year":"2022","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: Results from one cohort of MajesTEC-2, a phase 1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2022.40.16_suppl.8014","article-title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1","volume":"40","author":"Jakubowiak","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of Elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-Cell Maturation Antigen (BCMA)-directed therapies: Results from cohort a of the Magnetismm-3 Study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1182\/blood-2022-166854","article-title":"Magnetismm-4: An open label, phase 1B\/2 Umbrella Study of Elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Results from the Phase 3 Magnetismm-5 study safety lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood-2019-126818","article-title":"Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell\u2013engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC.; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180: RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: Preliminary results from a first-in-human trial","volume":"6","author":"Riley","year":"2022","journal-title":"HemaSphere"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1200\/JCO.2021.39.15_suppl.8044","article-title":"ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma","volume":"39","author":"Doucey","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-cell\u2013recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Fajardo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myelom","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","article-title":"Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1","volume":"40","author":"Minnema","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Phase 1\/2 results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1182\/blood-2022-162555","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 bispecific antibody: Patient-reported outcomes from MonumenTAL-1","volume":"140","author":"Touzeau","year":"2022","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: Phase 3 trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1182\/blood-2022-163260","article-title":"MonumenTAL-5: A phase 3 study of talquetamab versus belantamab mafodotin in patients with relapsed\/refractory multiple myeloma who received \u22654 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: Early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: Generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Futur. Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: Efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 Cohort 2c: Efficacy and safety of Idecabtagene Vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1182\/blood-2022-159141","article-title":"Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1","volume":"140","author":"Munshi","year":"2022","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2021.39.15_suppl.8013","article-title":"CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy","volume":"39","author":"Agha","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1182\/blood-2022-159169","article-title":"Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-directed CAR-T Cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 Cohort B 18-Month Follow-up","volume":"140","author":"Agha","year":"2022","journal-title":"Blood"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/hematology.2022000396","article-title":"Cellular therapy for multiple myeloma: What\u2019s now and what\u2019s next","volume":"2022","author":"Otero","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Wang, D., Wang, J., Hu, G., Wang, W., Xiao, Y., Cai, H., Jiang, L., Meng, L., Yang, Y., and Zhou, X. (2021). A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed\/Refractory Multiple Myeloma. Blood.","DOI":"10.1182\/blood.2020008936"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2021-148578","article-title":"CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome","volume":"138","author":"Serrano","year":"2021","journal-title":"Blood"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"abh1962","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Eyquem","year":"2022","journal-title":"Nat. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2021-154170","article-title":"Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma","volume":"138","author":"Cowan","year":"2021","journal-title":"Blood"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2022-164884","article-title":"Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience","volume":"140","author":"Ferreri","year":"2022","journal-title":"Blood"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1182\/blood-2022-166058","article-title":"Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience","volume":"140","author":"Sidana","year":"2022","journal-title":"Blood"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical Outcomes and Salvage Therapies in Patients with Relapsed\/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1182\/blood-2022-162682","article-title":"French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed\/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry","volume":"140","author":"Ferment","year":"2022","journal-title":"Blood"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.HS9.0000843628.63947.e4","article-title":"S184: Evaluating Teclistamab in patients with relapsed\/ refractory multiple myeloma following exposure to other B-Cell Maturation Antigen (Bcma)-Targeted Agents","volume":"6","author":"Touzeau","year":"2022","journal-title":"HemaSphere"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.HS9.0000846460.44039.3d","article-title":"P897 Updated results from the ongoing phase 1 study of elranatamab, a bcma targeted tcell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma","volume":"6","author":"Dalovisio","year":"2022","journal-title":"HemaSphere"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: Real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1182\/blood-2022-163809","article-title":"An updated safety and efficacy analysis of Venetoclax plus Daratumumab and dexamethasone in an expansion cohort of a phase 1\/2 Study of patients with t(11;14) relapsed\/refractory multiple myeloma","volume":"140","author":"Kaufman","year":"2022","journal-title":"Blood"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/blood-2022-158180","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in relapsed\/refractory multiple myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial","volume":"140","author":"Lonial","year":"2022","journal-title":"Blood"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2022-157945","article-title":"Mezigdomide (CC-92480), a potent, novel Cereblon E3 Ligase Modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1182\/blood-2022-158011","article-title":"Once weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in triple class refractory multiple myelom","volume":"140","author":"Schiller","year":"2022","journal-title":"Blood"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2022-162253","article-title":"Final Results from the First-in-Human Phase 1\/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Vogl","year":"2022","journal-title":"Blood"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: Does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:27Z","timestamp":1760123547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":241,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15082203"],"URL":"https:\/\/doi.org\/10.3390\/cancers15082203","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]}}}